SynthesisInflammation research : official journal of the European Histamine Research Society ... [et al.]2025
Short-chain fatty acids in the treatment of ulcerative colitis. Systematic review and meta-analysis.
Synthesis in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Rewriting Inflammation in IBD: Lipidomics from Pathogenesis to Clinical Application.Microorganisms · 2026Review
- Flos sophorae immaturus exosome-like nanovesicles alleviate ulcerative colitis by attenuating intestinal oxidative stress and inflammation through activating Aryl hydrocarbon receptor via gut microbiota and tryptophan metabolism regulation.Journal of nanobiotechnology · 2026Article
- Article
- Pneumococcal Endopeptidase O Attenuates Colitis by Inhibiting the Macrophage-CCL2 Axis and Reshaping Gut Microbiota.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND AND
objectiveInflammatory bowel diseases, including Crohn's disease and ulcerative colitis (UC), are chronic conditions characterized by intestinal inflammation. Soluble fiber is fermented by gut microbiota into short-chain fatty acids (SCFA), which possess anti-inflammatory properties. This review aimed to assess the efficacy of oral and topical SCFA administration in patients with UC.
methodsA systematic review with meta-analysis was conducted in accordance with PRISMA guidelines. Meta-analyses were performed using means and standard deviations to assess clinical and histological outcomes. Endoscopic criteria were also evaluated to determine the effectiveness of the intervention.
resultsNine studies compared SCFA supplementation with standard therapy, and one employed a crossover design. Oral SCFA, when combined with standard treatment, as associated with reductions in fecal calprotectin and C-reactive protein levels. Meta-analyses of topical SCFA administration revealed a standardized mean difference of - 0.29 ± 0.22, (95% CI: - 0.65 to 0.07; heterogeneity I
conclusionSCFA administration, either orally or topically, has been investigated as a potential adjunct to standard UC therapies. However, the current evidence is limited, particularly for oral administration, which has only been assessed in two studies. Further research is needed to clarify the potential role of SCFA administration.
Indexed as
Identifiers
41107619What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.